Hepatitis C patients who use intravenous drugs were cured at a high rate by Merck & Co.’s experimental therapy, a study found, a result that could put pressure on U.S. states to more broadly cover new treatments for a group that’s at high risk of reinfection. Many states require people with hepatitis C to prove that they abstain from drug use before getting covered through Medicaid, the U.S.’s state-run health program for the poor. In Merck’s study of 301 intravenous drug users, 95 percent of patients treated in the trial were cured...
↧